Physician profile
Christopher B King
NPI 1962637652
$1,152.67
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $88.78 · 2021: $86.18 · 2022: $184 · 2023: $389 · 2024: $79.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $289.32 | 2023-2024 | Gemtesa |
| Janssen Biotech, INC. | $137.87 | 2019-2021 | |
| Amgen INC. | $137.21 | 2022-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $105.90 | 2023 | Absorica Ld, Winlevi |
| Abbvie INC. | $85.76 | 2019-2021 | |
| Astellas Pharma US INC | $59.95 | 2019-2023 | Myrbetriq |
| Blue Earth Diagnostics | $57.83 | 2019-2020 | |
| Dermira, INC. | $41.41 | 2019-2020 | |
| Pfizer INC. | $37.29 | 2019-2022 | |
| Celgene Corporation | $31.80 | 2019 | |
| Coloplast Corp | $25.62 | 2019 | |
| Genzyme Corporation | $23.33 | 2020 | |
| Boston Scientific Corporation | $20.80 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.80 | 2022 | |
| Urovant Sciences INC | $17.71 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $16.64 | 2019 | |
| Merck Sharp & Dohme LLC | $16.41 | 2020 | |
| Myriad Genetic Laboratories, INC. | $14.71 | 2022 | |
| Ucb, INC. | $14.31 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.